Glaukos and Intratus have amended a global licensing agreement to include the treatment of presbyopia, according to a Glaukos press release.
The amendment adds presbyopia as an investigational application to the Eyelid Drug Delivery Platform. Glaukos will have a global exclusive license to research, develop, manufacture and commercialize Intratus’ delivery system for presbyopia treatment, the release said. Previously, Glaukos had licensing of the platform for the treatment of dry eye disease, glaucoma and other corneal disorders.
“We are excited to expand our partnership with